FIRST-308
The first phase 3 trial for patients whose bile duct cancer has outgrown the existing FGFR drugs.
Global, randomised; primary endpoint PFS. First US patient dosed 2025.
Setting
FGFR-altered cholangiocarcinoma refractory to chemotherapy and a first-generation FGFR inhibitor: tinengotinib vs FOLFOX/FOLFIRI
Phase
Phase 3
Sponsor
TransThera